Retrospective Study
Copyright ©The Author(s) 2025.
World J Gastroenterol. May 7, 2025; 31(17): 104579
Published online May 7, 2025. doi: 10.3748/wjg.v31.i17.104579
Table 1 Baseline characteristics of the cases, mean ± SD/n (%)
Characteristics
Total (n = 526)
Male (n = 238)
Female (n = 288)
P value
Age, year45.01 ± 13.7843.23 ± 13.5446.48 ± 13.820.007
BMI, Kg/m221.49 ± 3.2322.27 ± 3.2920.85 ± 3.04< 0.001
Course of disease, month (median IQR)48 (24, 120)48 (22.5, 120)48 (24, 96)0.584
ASA classificationTotal (n = 496)Male (n = 221)Female (n = 275)0.506
155 (11.1)23 (10.4)32 (11.6)
2428 (86.3)191 (86.4)237 (86.2)
313 (2.6)7 (3.2)6 (2.2)
Chicago classificationTotal (n = 437)Male (n = 199)Female (n = 238)0.219
165 (14.9)36 (18.1)29 (12.2)
2343 (78.5)149 (74.9)194 (81.5)
329 (6.6)14 (7.0)15 (6.3)
Follow-up period, month (median IQR)41.0 (21.3, 64.6)37.7 (19.9, 66.6)43.0 (22.5, 64.3)0.226
Previous treatment0.584
Pneumatic dilation58 (11.03)29 (12.18)29 (10.07)
Botox injection27 (5.13)10 (4.20)17 (5.90)
laparoscopic heller myotomy11 (2.09)6 (2.52)5 (1.74)
Tunnel length, cm (median IQR)12 (10, 12)12 (9.75, 12)12 (10, 12)0.074
Myotomy length, cm (median IQR)7 (5.6, 9)7 (6, 9)7 (6, 9)0.492
Myotomy length of esophagus, cm (median IQR)5 (4.7)5 (4, 7)5 (4, 7)0.369
Myotomy length of stomach, cm (median IQR)2 (2, 2)2 (2, 2)2 (2, 2)0.948